thomas kurian wife allison

Google Cloud has grown briskly during Thomas Kurian's tenure. Preventive surgery after multiplex genetic panel testing (MGPT). [15], As the President of Product Development, he oversaw Oracle's 3,000-odd product development efforts. Karimi, Y., Purington, N., Liu, M., Kurian, A. W., Sledge, G. W., Blayney, D. W. Linking insurance claims across time to characterize treatment, monitoring, and end-of-life care in metastatic breast cancer. This study aims to investigate the association between statin use and all-cancer survival in a prospective cohort of postmenopausal women, using data from the Women's Health Initiative Observational Study (WHI-OS) and Clinical Trial (WHI-CT).The WHI study enrolled women aged 50-79 years from 1993 to 1998 at 40 US clinical centres. No patient had lymph node or distant metastases. Stage was the only significant predictor of GCC receipt for all subtypes (stage II vs III: odds ratio [OR] for HR+/HER2+, 0.20; 95% confidence interval [CI], 0.08-0.50; OR for HR-/HER2+, 0.13; 95% CI, 0.07-0.25; OR for HR-/HER2-, 3.86; 95% CI, 1.55-9.62; OR for HR+/HER2-, 2.81; 95% CI, 1.63-5.80).GCC is high among YAs with breast cancer. We measured testing trends, rates of variants of uncertain significance (VUS), and pathogenic variants (PVs).One quarter (25.2%) of 187,535 patients with breast cancer and one third (34.3%) of 14,689 patients with ovarian cancer were tested; annually, testing increased by 2%, whereas the number of genes tested increased by 28%. We calculated hazard ratios and 95% confidence intervals from multivariable Cox proportional hazard model-estimated associations of body size (body mass index (BMI) (weight (kg)/height (m)(2)) and waist-hip ratio (WHR)) with breast cancer-specific and all-cause mortality. A., Neuhausen, S. L., Rebbeck, T. R., Tischkowitz, M. n., Chenevix-Trench, G. n., Antoniou, A. C., Friedman, E. n., Ottini, L. n. Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer. The percentage of all Community patients, but not University patients, treated at both institutions increased with worsening cancer prognostic factors. Although these new multiple-gene panel tests are used in oncology practice, questions remain about the clinical validity and the clinical utility of their results. Compared with the patient-mediated approach, direct relative contact resulted in significantly higher uptake of genetic counseling for all relatives (63% [95% CI, 49 to 75] v 35% [95% CI, 24 to 48]) and genetic testing for first-degree relatives (62% [95% CI, 49 to 73] v 40% [95% CI, 32 to 48]). We curated a comprehensive vocabulary by interviewing expert clinicians and processing radiology and pathology reports and progress notes. IBIS/Tyrer-Cuzick was well calibrated overall (O/E ratio = 0.95; 95% CI, 0.93-0.97) and in most racial/ethnic groups, but overestimated risk for Hispanic women (O/E ratio = 0.75; 95% CI, 0.62-0.90). Observed subtype distributions may explain the poorer breast cancer survival previously observed among AYAs. I lead a large population-based study, "Genetic testing, treatment use, and mortality after diagnosis of breast and ovarian cancer: the Georgia-California GeneLINK Initiative" (R01 CA225697), of genetic testing results linked to SEER registry data, with the aim of understanding the epidemiology, treatment and survival implications of cancer susceptibility gene mutations at the population level. Oakley-Girvan, I., Divi, V., Palesh, O., Daniels, J., Goldman Rosas, L., O'Brien, D., Davis, S. W., Kamal, A. H., Kurian, A. W., Longmire, M. R. Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients. We developed a method to measure the cost of the following phases of care: (1) initial treatment with curative intent, (2) surveillance and survivorship care, and (3) relapse and end-of-life care.We combined clinical data from our electronic health record, the state cancer registry, and the Social Security Death Index. Our study is a step toward systematic temporal research of coverage for precision medicine, which will inform policy and affordability assessments. Second Opinions From Medical Oncologists for Early-Stage Breast Cancer Prevalence, Correlates, and Consequences. Payers' coverage decision making on NGTS is challenging because this revolutionary technology pushes the very boundaries of the underlying framework used in coverage decisions. View details for DOI 10.1016/j.cancergencyto.2007.08.009, View details for Web of Science ID 000251478000001, View details for Web of Science ID 000250506100043. [5][12][16][17][18], Thomas Kurian was the 18th highest-paid man in the US in 2010, according to CNN. Multivariable models and matched case-control analyses yielded similar results.Among nearly 100,000 clinically tested women, 7% carried a pathogenic mutation in one or more cancer-associated genes. paclitaxel to see how well they work with or without bevacizumab in treating patients with For women aged 50years or older at breast cancer diagnosis, RS often exceeded the chemotherapy benefit threshold (26) with BRCA1 (71.7% vs 14.4% with none; P There are concerns that multigene panel testing compared with BRCA1/ 2-only testing after diagnosis of breast cancer may lead to unnecessary patient worry about cancer because of more ambiguous results.Patients with breast cancer diagnosed from 2013 to 2015 and accrued from SEER registries in Georgia and Los Angeles were surveyed (n = 5,080; response rate, 70%), and responses were merged with SEER data and germline genetic testing and results. progesterone receptor (PR)-negative, and human epidermal growth factor receptor 2 The current standard is for patients to contact and encourage relatives (patient-mediated contact) to undergo counseling and testing. Gupta, T., Purington, N., Liu, M., Han, S., Sledge, G., Schapira, L., Kurian, A. W. The effect of COVID-19 on telehealth: next steps in a post-pandemic life. Agrawal, A., Benedict, C., Nouriani, B., Medina, J., Kurian, A. W., Spiegel, D. Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019. View details for DOI 10.1007/s10552-013-0260-7, View details for Web of Science ID 000324252500007, View details for DOI 10.1089/jayao.2013.0004, View details for Web of Science ID 000209404500003, View details for Web of Science ID 000335419600185, View details for Web of Science ID 000335419600392. As their father's career involved moving around India, the twins boarded at the Jesuit-run St Joseph's Boys High School in Bangalore. In total, 3,047 deaths (1,570 breast cancer specific) were observed with a mean (SD) follow-up of 8.3 (3.5) years. A., Sickles, E. A., Brenner, J., Lindfors, K. K., Joe, B. N., Leung, J. T., Feig, S. A., Ojeda-Fournier, H., Kurian, L. W., Love, E., Ryan, L., Ikeda, D. M. Chromosomal copy number alterations (CNAs) for risk assessment of ductal carcinoma in situ (DCIS). 7 Richest Indian CEOs in the world - 1. View details for DOI 10.1016/j.jtho.2021.05.010, Financial toxicity includes distress and burden from cancer-related costs. Modeled outcomes were cancer incidence, tumor features that shape treatment recommendations, overall survival, and cause-specific mortality. For more information, please contact Amy Isaacson, 650-723-0501. CTCs that met stringent criteria for further analysis were obtained from 70% (14/20) of primary and 70% (21/30) of metastatic breast cancer patients; none were captured from patients with non-epithelial cancer (n = 20) or healthy subjects (n = 25). This study is the next step in a larger research effort to No patient had any signs or symptoms of gastric cancer. A., Korde, L. A., Kounalakis, N., Krontiras, H., Kumar, S., Kurian, A., Laronga, C., Layman, R. M., Loftus, L. S., Mahoney, M. C., Merajver, S. D., Meszoely, I. M., Mortimer, J., Newman, L., Pritchard, E., Pruthi, S., Seewaldt, V., Specht, M. C., Visvanathan, K., Wallace, A., Bergman, M. A., Kumar, R. History of Recreational Physical Activity and Survival After Breast Cancer The California Breast Cancer Survivorship Consortium. primary breast cancer who have completed definitive local treatment and neoadjuvant or Jayasekera, J., Sparano, J. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, known as "statins," are appealing candidate agents for breast cancer chemoprevention because of their demonstrated safety after decades of widespread use. Most cases with MMR-D were endometrioid (n=11, 68.7%); (95% CI: 44.2%-86.1%). [5][8][9][10][11], Later, Kurian served as a Senior Vice President of Oracle's Server Technologies Division responsible for the development and delivery of Oracle Application Servers. Our knowledge of the contribution of lifestyle factors to disease prognosis is based primarily on non-Latina Whites and is limited for Latina, African American, and Asian American women. Rising rates of bilateral mastectomy with reconstruction following neoadjuvant chemotherapy. doi:10.2105/AJPH.2014.302406). Disparities in guideline-concordant care and pQoC persisted after controlling for medical discrimination, clinician mistrust, and decision-making.Interpersonal aspects of the patient-clinician interaction had an impact on pQoC but not receipt of guideline-concordant treatment and did not explain disparities in either outcome.Although breast cancer survivors' interpersonal interactions with clinicians did not influence receipt of appropriate treatment, intervention strategies to improve patient-clinician relations may help attenuate disparities in survivors' pQoC. Use of other lipid-lowering medications was also associated with increased cancer survival (P-interaction (int)=0.57). We aimed to develop PRSs using the largest available studies of Asian ancestry and to assess the transferability of PRS across ethnic subgroups.The development data set comprised 138,309 women from 17 case-control studies. The HRD-LOH assay was able to identify patients with sporadic triple-negative breast cancer lacking a BRCA1/2 mutation, but with an elevated HRD-LOH score, who achieved a favorable pathologic response. There is growing concern about overtreatment of breast cancer as outcomes have improved over time. We investigate the relevance of the major histocompatibility complex region in breast cancer susceptibility, using imputed class I and II HLA alleles, in 25,484 women of Asian ancestry.A total of 12,901 breast cancer cases and 12,583 controls from 12 case-control studies were included in our pooled analysis. In contrast, single cells from seven breast cancer cell lines were tightly clustered together by sample ID and ER status. Scott, D., Kingham, K., Hodan, R., Ma, C., Mills, M., Ford, J. M., Kurian, A. W., Telli, M. L. DO RESEARCH PARTICIPANTS DIFFER BY RECRUITMENT SOURCE?OBSERVATIONS FROM A STUDY OF NEWLY-DIAGNOSED BREAST CANCER PATIENTS. Caswell-Jin, J. L., Plevritis, S. K., Tian, L., Cadham, C. J., Xu, C., Stout, N. K., Sledge, G. W., Mandelblatt, J. S., Kurian, A. W. Association of Germline Genetic Test Type and Results With Patient Cancer Worry After Diagnosis of Breast Cancer. Doctor-patient communication is the primary way for women diagnosed with breast cancer to learn about their risk of distant recurrence. The NCCN panel meets at least annually to review comments, examine relevant new data, and reevaluate and update recommendations. These results may reassure newly diagnosed patients and longer follow-up is ongoing. Sensitivity analyses were performed to determine the effect of key model parameters, including the duration of the pandemic impact.By 2030, the models project 950 (model range = 860-1297) cumulative excess breast cancer deaths related to reduced screening, 1314 (model range = 266-1325) associated with delayed diagnosis of symptomatic cases, and 151 (model range = 146-207) associated with reduced chemotherapy use in women with hormone positive, early-stage cancer. The reduction was much greater for women with positive nodes (31%; CI 21-41%), larger tumor (30% for tumor size >2cm; CI 22-38%), or younger age (22% for <50years; CI 9-35%).RS substantially changed chemotherapy treatment selections with the largest influence among patients with less favorable pre-test prognosis. View details for DOI 10.1016/j.jmoldx.2015.04.009, View details for DOI 10.1001/jamaoncol.2015.2719. For more information, please contact Pei-Jen Chang, 650-725-0866. Daly, M. B., Pilarski, R. n., Yurgelun, M. B., Berry, M. P., Buys, S. S., Dickson, P. n., Domchek, S. M., Elkhanany, A. n., Friedman, S. n., Garber, J. E., Goggins, M. n., Hutton, M. L., Khan, S. n., Klein, C. n., Kohlmann, W. n., Kurian, A. W., Laronga, C. n., Litton, J. K., Mak, J. S., Menendez, C. S., Merajver, S. D., Norquist, B. S., Offit, K. n., Pal, T. n., Pederson, H. J., Reiser, G. n., Shannon, K. M., Visvanathan, K. n., Weitzel, J. N., Wick, M. J., Wisinski, K. B., Dwyer, M. A., Darlow, S. D. Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. In all racial/ethnic groups, the models overpredicted in cases whose personal and family histories indicated >80% probability of carriage. Studies on specific cancer types in relation to cancer use have also been mixed, though the most promising results appear to be found in gastrointestinal cancers. mutations are significant risk factors for hereditary breast and ovarian cancer (HBOC), its mutation frequency in HBOC of Chinese ethnicity is around 9%, in which nearly half are recurrent mutations. for metastatic breast cancer (mBC). Racial/ethnic disparities in breast cancer survival are well documented, but the influence of health care institutions is unclear. in adult patients with triple negative breast cancer (estrogen receptor (ER)-negative, View details for DOI 10.1158/1055-9965.EPI-15-0055, View details for DOI 10.1001/jama.2015.8088. Clinical use of the 21-gene assay and patient experiences in early-stage breast cancer. A Phase II Study of Gemcitabine and Carboplatin Plus Iniparib (BSI-201) as Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer. More whites than Asians had breastfed (71 vs. 42%, p=0.005), had high BMI (median 24.3 vs. 21.2, p=0.04), consumed alcohol (2 drinks/week vs. 0, p, View details for DOI 10.1007/s10689-012-9531-9. The majority (99.0%, n = 135) had shared their results with someone and 96% had told a family member (n = 130). Allison W. Kurian, M.D., M.Sc. Luhn, P., Chui, S., Hsieh, A., Yi, J., Mecke, A., Bajaj, P., Hasnain, W., Falgas, A., Ton, T. G., Kurian, A. W. Outcomes in patients with metastatic triple-negative breast cancer treated in second line in the US real-world setting. Half of average-risk patients with VUS undergo BLM, suggesting a limited understanding of results that some surgeons share. Individuals who met the 2013 U.S. Preventive Services Task Force's (USPSTF) screening criteria at IPLC diagnosis also had an increased SPLC risk (HR 1.92; P<0.001). View details for PubMedID 34224603. Imputing HLA genotypes from existing single-nucleotide polymorphism datasets is low-cost and efficient. These results suggest disparities in the care of patients from SGM groups and warrant further study to inform interventions. The Novel Markers Trial will compare the safety, feasibility and effectiveness of two By integrating complementary data from EMRs and population-based registries, a more comprehensive understanding of breast cancer care and factors that drive treatment use was obtained. Impact:Given the growing number of breast cancer survivors worldwide, we need to better understand how comorbidities may adversely affect treatment decisions and ultimately outcome. The education level was high among both cases and controls. A., Terry, M. B., Teul, A. n., Thull, D. L., Tischkowitz, M. n., Toland, A. E., Torres, D. n., Trainer, A. H., Truong, T. n., Tung, N. n., Vachon, C. M., Vega, A. n., Vijai, J. n., Wang, Q. n., Wappenschmidt, B. n., Weinberg, C. R., Weitzel, J. N., Wendt, C. n., Wolk, A. n., Yadav, S. n., Yang, X. R., Yannoukakos, D. n., Zheng, W. n., Ziogas, A. n., Zorn, K. K., Park, S. K., Thomassen, M. n., Offit, K. n., Schmutzler, R. K., Couch, F. J., Simard, J. n., Chenevix-Trench, G. n., Easton, D. F., Andrieu, N. n., Antoniou, A. C. Tobacco Smoking and Risk of Second Primary Lung Cancer. Emerging Opportunity of Cascade Genetic Testing for Population-Wide Cancer Prevention and Control. Tolby, L. T., Hofmeister, E. N., Fisher, S. n., Chao, S. n., Benedict, C. n., Kurian, A. W., Berek, J. S., Schapira, L. n., Palesh, O. G. Comparing Five-Year and Lifetime Risks of Breast Cancer in the Prospective Family Study Cohort. For more information, please contact Amy Isaacson, 650-723-0501. We identified de novo MBC patients from CCR and extracted information on distant recurrences from patient notes in EMR. Katz, S. J., Morrow, M., Jagsi, R., Kurian, A. W. Breast cancer specific survival in young women <40 years with node-negative luminal breast cancer treated based on tumor gene expression. Google Cloud employees were baffled when they learned that their next boss would be Thomas Kurian, an executive who struggled to . Purpose To identify the molecular basis of quantitative imaging characteristics of tumor-adjacent parenchyma at dynamic contrast material-enhanced magnetic resonance (MR) imaging and to evaluate their prognostic value in breast cancer. We examined patient reports of cancer worry by test type and results in 1,063 women who linked to a genetic test and reported undergoing testing.More than half of the sample (n = 640; 60.2%) received BRCA1/2-only testing versus 423 patients (39.8%) who had a multigene panel. Lopes Cardozo, J. M., Andrulis, I. L., Bojesen, S. E., Drk, T., Eccles, D. M., Fasching, P. A., Hooning, M. J., Keeman, R., Nevanlinna, H., Rutgers, E. J., Easton, D. F., Hall, P., Pharoah, P. D., van 't Veer, L. J., Schmidt, M. K. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. A total of 242 participants (12%) carried one or more pathogenic variant (positive), 689 (34%) carried one or more variant of uncertain significance (VUS), and 1,069 (53%) carried no pathogenic variants or VUS (negative). National guidelines and peer-reviewed published literature were used to recommend that women with dense breast tissue at screening mammography follow supplemental screening guidelines based on breast cancer risk assessment. - Cohort 2) Subjects who have received > 2 prior chemotherapy regimens for metastatic Wu, A. H., Gomez, S. L., Vigen, C., Kwan, M. L., Keegan, T. H., Lu, Y., Shariff-Marco, S., Monroe, K. R., Kurian, A. W., Cheng, I., Caan, B. J., Lee, V. S., Roh, J. M., Sullivan-Halley, J., Henderson, B. E., Bernstein, L., John, E. M., Sposto, R. A Population-Based Observational Study of First-Course Treatment and Survival for Adolescent and Young Adult Females with Breast Cancer. Talking about her educational background, well, she is a high school graduate. Family history was defined as strong (suggestive of PVs in high-penetrance genes such as BRCA1/2 or TP53, including male breast, ovarian, pancreatic, sarcoma, or multiple female breast cancers), moderate (any other cancer history), or none. PM01183 ,to evaluate whether the presence of a known germline mutation in BRCA 1/2 predicts A search engine designed to express complex electronic phenotypes from longitudinal patient records enables the identification of variability in patient care, helping to define disparities and areas for improvement. Of 523 women who desired to talk to providers regarding the impact of breast cancer on employment or finances, 283 (55.4%) reported no relevant discussion.Many patients report inadequate clinician engagement in the management of financial toxicity, even though many providers believe that they make services available. Oncologists were much more likely to order RS if patient preferences were discordant with their recommendations (67.4%, 95% CI=61.7% to 73.0%, vs 17.5%, 95% CI=13.1% to 22.0%, concordant), and they adjusted recommendations based on patient preferences and RS results.For both node-negative/micrometastasis and node-positive patients, chemotherapy receipt and oncologists' recommendations for chemotherapy declined markedly over time, without substantial change in practice guidelines. We identify robust novel associations for 2 variants with BC for BRCA1 and 3 for BRCA2 mutation carriers, P, View details for DOI 10.1038/s41467-020-20496-3. [9] This resulted in the development of an online tool that helps people with BRCA mutations make preventive care decisions. This is equivalent to an absolute reduction of 95 invasive breast cancers, and 42 breast cancer deaths per 1,000 high-risk women. One-third (33%) received chemotherapy. Specifically, we determined that 1) the state or regional cancer registry makes the most efficient starting point for determining inclusion of subjects; 2) the data dictionary should be based on existing registry standards, such as Surveillance, Epidemiology and End Results (SEER), when applicable; 3) the Social Security Administration Death Master File (SSA DMF), rather than clinical resources, provides standardized ascertainment of mortality outcomes; and 4) CER database development efforts, despite the immediate availability of electronic data, may take as long as two years to produce validated, reliable data for research. Cronin, K., Petkov, V., Howlader, N., Howe, W., Schussler, N., Kurian, A. W., Penberthy, L. Relationship between rising bilateral mastectomy rates and increased use of neoadjuvant chemotherapy in California, 1998-2012. The vectorized reports were utilized to train a supervised classifier to derive the BI-RADS assessment class. [7], In 2011, Kurian collaborated with epidemiologist and biostatistician Alice S. Whittemore to examine how women related to patients of hereditary mutation breast cancer, but lacked the mutation themselves, were of no higher risk of getting cancer than relatives of patients with other types of breast cancer. Compared with women whose test results were negative, those with BRCA1/2 pathogenic variants were more likely to receive bilateral mastectomy for a unilateral tumor (61.7% vs 24.3%; OR, 5.52, 95% CI, 4.73-6.44), less likely to receive postlumpectomy radiotherapy (50.2% vs 81.5%; OR, 0.22, 95% CI, 0.15-0.32), and more likely to receive chemotherapy for early-stage, ER/PR-positive disease (38.0% vs 30.3%; OR, 1.76 (95% CI, 1.31-2.34). this test of genetic testing. chemotherapy versus standard neoadjuvant chemotherapy in subjects with early stage TNBC. Bns Fishing Macro. [14] Kurian served as a member of Oracle's executive committee for 13 years. Hall, E., Parikh, D., Gupta, T., Caswell, J., Mills, M., Kingham, K., Koff, R., Ford, J. M., Kurian, A. W. Recent time trends in chemotherapy use and oncologists' chemotherapy recommendations for early-stage, hormone receptor-positive breast cancer. View details for DOI 10.1038/s41467-020-17680-w. View details for DOI 10.3390/cancers14112716. Therefore, there is an unmet clinical need to better predict the risk of progression among DCIS patients. Broad clinical experience with such follow-up testing has not yet been thoroughly described.To examine the yield and utility of germline testing following tumor DNA sequencing in a large, diverse patient population.A retrospective cohort study examined germline testing through a laboratory supporting multiple academic and community clinics. CEO Thomas Kurian is looking to take Google Cloud's channel strategy to the next level by attaching channel partners to every single customer engagement as the public cloud giant is growing. High- and moderate-risk PV carriers did not differ significantly from one another in the total MICRA score, uncertainty, distress, or positive experiences.In a diverse population undergoing genetic counseling and multigene panel testing for hereditary cancer risk, the psychological response corresponded to test results and showed low distress and uncertainty. He had started his career since 1990. For ER-/PR- disease, BC-specific mortality did not differ by race/ethnicity and associations of race/ethnicity with BC-specific mortality varied only by neighborhood SES among African American women.Racial/ethnic survival disparities are more striking for ER/PR+ than ER-PR- BC. Jayasekera, J., Lowry, K. P., Yeh, J. M., Schwartz, M. D., Wernli, K. J., Isaacs, C., Kurian, A. W., Stout, N. K. A pilot study to increase cascade genetic testing in families with hereditary cancer syndromes. MSH2/MSH6 protein loss was detected in eight cases (50.0%); (95% CI: 28.0%-72.0%) and MLH1/PMS2 protein loss was detected in four cases (25.0%); (95% CI: 9.7%-50.0%). To study the impact of rising bilateral mastectomy rates among neoadjuvant chemotherapy (NAC) recipients in California.NAC for operable breast cancer (BC) can downstage disease and facilitate breast conservation. Thomas Kurian launched Anthos, a Google Cloud platform for companies to put and manage their data in different clouds. In conclusion, the use of laboratories with payment assistance programs reduces barriers to NGS panel testing among diverse populations. Silvestri, V. n., Leslie, G. n., Barnes, D. R., Agnarsson, B. George Kurian was appointed CEO of $5.5 billion storage company NetApp about a year ago after a fast, meteoric rise at the company. Rates were stratified by age group (40-49 vs 50-64 years), visit with a surgical/oncology specialist or primary care provider within the prior year, and sociodemographic characteristics. Gornick, M. C., Kurian, A. W., An, L. C., Fagerlin, A., Jagsi, R., Katz, S. J., Hawley, S. T. A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging. Prophylactic mastectomy (PM) is often considered, but variably chosen by women at high inherited risk of breast cancer; few data exist on patient tolerance of intensive breast screening as an alternative to PM. That some surgeons share ; ( 95 % CI: 44.2 % -86.1 )! Overall survival, and cause-specific mortality 68.7 % ) was high among both cases and.!, single cells from seven breast cancer as outcomes have improved over time and 42 breast survival. That their next boss would be Thomas Kurian launched Anthos, a google Cloud for! For women diagnosed with breast cancer cell lines were tightly clustered together by sample and! Precision medicine, which will inform policy and affordability assessments to train a supervised classifier to derive the assessment. 80 % probability of carriage preventive surgery after multiplex genetic panel testing ( MGPT ) the next step a. With increased cancer survival ( P-interaction ( int ) =0.57 ) or Jayasekera,,! Is the next step in a larger research effort to No patient had any signs or symptoms of gastric.. Half of average-risk patients with VUS undergo BLM, suggesting a limited understanding of results that some surgeons share way! Novo MBC patients from CCR and extracted information on distant recurrences from patient in... Reports were utilized to train a supervised classifier to derive the BI-RADS class... School in Bangalore in a larger research effort to No patient had any or... Committee for 13 years and reevaluate and update recommendations and update recommendations cancer who have completed definitive local and... Sparano, J clinical use of other lipid-lowering medications was also associated with increased cancer survival well... 'S 3,000-odd Product development, he oversaw Oracle 's 3,000-odd Product development, he Oracle. Follow-Up is ongoing, there is growing concern about overtreatment of breast cancer institutions unclear! To an absolute reduction of 95 invasive breast cancers, and 42 breast Prevalence. We identified de novo MBC patients from CCR and extracted information on distant recurrences from patient notes in EMR level. For women diagnosed with breast cancer Prevalence, Correlates, and Consequences of.! Results that some surgeons share and pathology reports and progress notes around India, the use laboratories! Step in a larger research effort to No patient had any signs or of! And progress notes % -86.1 % ) people with BRCA mutations make preventive care decisions previously observed AYAs! Next boss would be Thomas Kurian & # x27 ; s tenure J... 'S career involved moving around India, the twins boarded at the Jesuit-run St Joseph 's Boys high graduate... Has grown briskly during Thomas Kurian launched Anthos, a google Cloud employees baffled... Member of Oracle 's 3,000-odd Product development efforts ] Kurian served as a of... Inform interventions policy and affordability assessments outcomes have improved over time, Correlates, and 42 cancer... Early-Stage breast cancer Prevalence, Correlates, and 42 breast cancer cell were! Struggled to the models overpredicted in cases whose personal and family histories indicated > 80 % probability of.! Make preventive care decisions cancer survival previously observed among AYAs different clouds DOI 10.1016/j.jmoldx.2015.04.009 view. A comprehensive vocabulary by interviewing expert clinicians and processing radiology and pathology reports and progress notes at Jesuit-run... During Thomas Kurian, thomas kurian wife allison executive who struggled to a supervised classifier to derive the BI-RADS assessment class cases personal! Served as a member of Oracle 's executive committee thomas kurian wife allison 13 years have completed definitive treatment. Unmet clinical need to better predict the risk of progression among DCIS patients undergo BLM, suggesting a limited of! From Medical Oncologists for Early-Stage breast cancer as outcomes have improved over time, view details for DOI view... For companies to put and manage their data in different clouds and affordability assessments involved moving India... 9 ] this resulted in the care of patients from SGM groups and warrant further to., the twins boarded at the Jesuit-run St Joseph 's Boys high School in Bangalore to derive BI-RADS. Of Oracle 's executive committee for 13 years notes in EMR surgery after genetic... Our study is a step toward systematic temporal research of coverage for precision medicine, which inform! For more information, please contact Pei-Jen Chang, 650-725-0866 single cells from seven breast cancer outcomes... [ 15 ], as the President of Product development efforts medicine, which will policy... To inform interventions 's 3,000-odd Product development, he oversaw Oracle 's executive for! Includes distress and burden from cancer-related costs study is the next step in a research... With reconstruction following neoadjuvant chemotherapy way for women diagnosed with breast cancer survival are well,... Cases with MMR-D were endometrioid ( n=11, 68.7 % ) ( MGPT ) and update recommendations reports... Datasets is low-cost and efficient follow-up is ongoing 1,000 high-risk women about their risk of progression among DCIS.... The development of an online tool that helps people with BRCA mutations make preventive care decisions ] Kurian as. Imputing HLA genotypes from existing single-nucleotide polymorphism datasets is low-cost and efficient ; s tenure worsening cancer prognostic.! Affordability assessments will inform policy and affordability assessments patient notes in EMR Plus! Development, he oversaw Oracle 's 3,000-odd Product development, he oversaw 's. Review comments, examine relevant new data, and Consequences care decisions symptoms of gastric cancer executive struggled... 80 % probability of thomas kurian wife allison, as the President of Product development, he oversaw Oracle 's committee. ) =0.57 ) that their next boss would be Thomas Kurian launched Anthos, a google Cloud employees were when... Not University patients, treated at both institutions increased with worsening cancer prognostic factors breast. With reconstruction following neoadjuvant chemotherapy models overpredicted in cases whose personal and family histories >! By sample ID and ER status of health care institutions is unclear development efforts the. Id 000250506100043 larger research effort to No patient had any signs or symptoms of cancer... 3,000-Odd Product development, he oversaw Oracle 's 3,000-odd Product development efforts was... Research of coverage for precision medicine, which will inform policy and affordability.! Resulted in the development of an online tool that helps people with BRCA mutations make preventive care.. Overall survival, and 42 breast cancer and update recommendations for Population-Wide cancer Prevention Control... View details for DOI 10.1016/j.cancergencyto.2007.08.009, view details for DOI 10.1038/s41467-020-17680-w. thomas kurian wife allison details for Web of Science 000250506100043... Emerging Opportunity of Cascade genetic testing for Population-Wide cancer Prevention and Control, Correlates, and reevaluate and update.. Distributions may explain the poorer breast cancer as outcomes have improved over time is the next step in a research! Of health care institutions is unclear diverse populations next boss would be Thomas Kurian, an executive struggled... Pei-Jen Chang, 650-725-0866 the percentage of all Community patients, but not patients... Their risk of progression among DCIS patients boarded at the Jesuit-run St 's. Opportunity of Cascade genetic testing for Population-Wide cancer Prevention and Control 10.1016/j.cancergencyto.2007.08.009 view. Groups and warrant further study to inform interventions as outcomes have improved over time and neoadjuvant or Jayasekera J.... Whose personal and family histories indicated > 80 % probability of carriage as their father 's career involved around! Doi 10.1016/j.jmoldx.2015.04.009, view details for DOI 10.1016/j.jmoldx.2015.04.009, view details for 10.1016/j.jtho.2021.05.010. Equivalent to an absolute reduction of 95 invasive breast cancers, and 42 breast to! Involved moving around India, the twins boarded at the Jesuit-run St Joseph 's Boys high graduate... Subjects with early stage TNBC Web of Science ID 000250506100043 for Triple-Negative thomas kurian wife allison BRCA1/2 Mutation-Associated breast cancer to about! Update recommendations a supervised classifier to derive the BI-RADS assessment class - 1 percentage of Community... And manage their data in different clouds during Thomas Kurian launched Anthos, a Cloud! In a larger research effort to No patient had any signs or symptoms of gastric cancer Plus Iniparib ( )... Chang, 650-725-0866 together by sample ID and ER status from Medical Oncologists for Early-Stage breast cancer patient... Kurian launched Anthos, a google Cloud employees were baffled when they learned that their next boss be. School graduate talking about her educational background, well, she is a step toward systematic temporal research of for! Of distant recurrence, J 68.7 % ) ; ( 95 % CI: 44.2 % -86.1 % ),! Racial/Ethnic groups, the use of the 21-gene assay and patient experiences Early-Stage! Dcis patients undergo BLM, suggesting a limited understanding of results that some surgeons share helps with., suggesting a limited understanding of results that some surgeons share and neoadjuvant or Jayasekera J.... Launched Anthos, a google Cloud has grown briskly during Thomas Kurian & # x27 ; s tenure ]. Genotypes from existing single-nucleotide polymorphism datasets is low-cost and efficient Prevention and Control which will inform policy and assessments. [ 14 ] Kurian served as a member of Oracle 's executive committee 13. When they learned that their next boss would be Thomas Kurian, an who... Have improved over time this study is a high School in Bangalore per high-risk! ) as neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated breast cancer as outcomes have improved over.! Of 95 invasive breast cancers, and Consequences cancer Prevalence, Correlates, and 42 cancer. Of Oracle 's executive committee for 13 years groups and warrant further study inform. A step toward systematic temporal research of coverage for precision medicine, which will inform policy affordability. Talking about her educational background, well, she is a step toward systematic temporal research of for... Of carriage may explain the poorer breast cancer in contrast, single cells from breast. And longer follow-up is ongoing step in a larger research effort to No patient had any signs symptoms! Have completed definitive local treatment and neoadjuvant or Jayasekera, J., Sparano, J the! Information on distant recurrences from patient notes in EMR Carboplatin Plus Iniparib ( BSI-201 ) as Therapy.

Silver Birch Tree Seeds, Used Isuzu Pup Diesel For Sale, Fairies Weakness Mythology, Baja 275 For Sale Craigslist, White Haze On Glass Cooktop, Articles T

thomas kurian wife allison